Immunobiological drugs in the treatment of rheumatic diseases
Journal Title: Нирки - Year 2019, Vol 8, Issue 3
Abstract
Rheumatic diseases (RD) are among the most common chronic diseases of the musculoskeletal system and connective tissue which are found in both adults and children. The cause of these pathological conditions can be changes in the functioning of the immune system, inflammation, infections and other factors. In some cases, they lead to disability and have a significant impact on the quality of life and lifetime. There are non-pharmacological and pharmacological treatments for RD. The first line (non-pharmacological) treatment of most RDs consists in changing the lifestyle (exercises, correct diet, smoking cessation). Standard pharmacological treatment includes non-steroidal anti-inflammatory drugs, glucocorticoids, anti-inflammatory drugs that suppress acute phase response, help reduce the level of autoantibodies. Unfortunately, although non-steroidal anti-inflammatory drugs help control RD symptoms reducing pain, swelling and inflammation, they do not slow down the disease progression. This also refers to glucocorticoids which are anti-inflammatory hormones associated with cortisol, a steroid produced naturally in the body. Despite their advantages, glucocorticoids have significant side effects including diabetes, osteoporosis, hypertension, cataract and susceptibility to infections. In recent years, new data on the pathogenesis of rheumatic diseases has been obtained that has contributed to the possibility of creating innovative immunobiological drugs. The development of such drugs has revolutionized the therapeutic approach to chronic rheumatic diseases, especially in patients who are resistant to standard treatment. The mechanism of action of these immunobiological drugs is based on the inhibition of specific or molecular targets directly involved in the disease pathogenesis. They include tumor necrosis factor blockers, interleukin-1, -6, 17A receptor antagonists, CD20, CD80/CD86 blockers and T-cell costimulation blocker. Their use allows us to improve the prognosis and achieve clinical remission in a significant number of patients.
Authors and Affiliations
O. O. Melnyk
Keywords
Related Articles
- EP ID EP630032
- DOI 10.22141/2307-1257.8.3.2019.176456
- Views 115
- Downloads 0
Application of genetic testing in steroid-resistant nephrotic syndrome
Nephrotic syndrome, one of the most frequent kidney conditions affecting patients of all ages, has significant genetic composition, especially in individuals who do not respond to glucocorticoid treatment. The recent dev...
Clinical Nephrology in Mutual Integration of Medical Professions
.
Hypertension Canada’s 2017 Guidelines for the Diagnosis, Assessment, Prevention, and Treatment of Pediatric Hypertension
.
Guideline Summary KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update
Guideline Summary "KDOQI clinical practice guideline for hemodialysis adequacy", 2015 update
Chronic kidney disease and anemia: application of ferrous bisglycinate chelate for correction of iron deficiency in patients with chronic kidney disease
Anemia is a component of chronic kidney disease, having erythropoietin- and iron deficiency nature. 2012 KDIGO guidelines determine anemia as a hemoglobin concentration < 120 g/l in women and < 130 g/l in men. An iron de...